IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor... Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
- Mechanism
- Curator reviewed
IGN301 is based on an anti-idiotype antibody designed to trigger an immune response to Lewis Y, a carbohydrate molecule frequently overexpressed in tumor cells of epithelial origin such as lung, colon, breast, prostate or ovarian cancer.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Code names
- IGN301
Which companies are running trials of IGN301, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account